Nexstim logo

Nexstim Plc Key Technology Patent Granted in US

28 June 2016

- Strengthened patent estate around Nexstim’s cutting-edge technology and software
Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that the United States Patent and Trademark Office ("USPTO") has granted a key patent covering its method and system for determining the status of the motor cortex and corticospinal pathways. This unique way of applying non-invasive magnetic stimulation pulses in combination with electromyography (EMG) measurement can be used to obtain an input-output curve and estimated motor threshold in one fast scan lasting 60 to 90 seconds.

Nexstim’s Navigated Brain Stimulation (NBS) is the world’s most advanced navigated Transcranial Magnetic Stimulation (TMS) system and the only one able to model the electric field in the brain. E-field and EMG response based navigation enables enhanced accuracy, repeatability and dose control, to transform TMS as a clinical tool for personalised therapy.

This approval is in addition to the Company’s patents granted in China. Nexstim’s patent portfolio includes 83 granted patents and 70 pending patents in 26 patent families.

Commenting on the announcement, Martin Jamieson, Chairman and CEO of Nexstim, said: “Nexstim’s technology is leading the way in navigated brain stimulation and this approval adds further global validation of our pioneering fully integrated NBS and NBT® technology.”

NEXSTIM PLC
Martin Jamieson, Chairman and CEO

For further information please visit www.nexstim.com or contact:

Nexstim +44 771 516 3942
Martin Jamieson, Chairman and Chief Executive Officer martin.jamieson@nexstim.com

UB Securities Ltd (Certified Adviser) +358 (0)9 2538 0246

Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Laura Thornton nexstim@consilium-comms.com

About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) system for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a system called Navigated Brain Therapy (NBT®) which is CE-marked for major depression and stroke therapy. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.

About Transcranial Magnetic Stimulation (TMS)
TMS uses an induction coil in which a time-varying magnetic field is generated to induce an electric E-field within the brain. The neurons at the locations of the brain exposed to a strong enough E-field will become activated, or stimulated. In NBS, the E-field induced in the brain by a TMS induction coil device is shown as an overlay on a graphical display of an anatomical representation of the subject's brain. By viewing the display, a user can visualise the E-field and, therefore, interactively position the TMS coil device, in real time, in relation to the brain to stimulate a target site. The response from the stimulation is measured with an integrated EMG to accurately record the size and latencies MEP caused by the stimulation. To accurately personalize the dose level to each individual the motor threshold needs to be obtained. Optimizing E-field generation and individually defining response level an optimal stimulation dose can be accurately and repeatedly administered.

Back to Press Releases